Finance

Lists
Why is 4AB down 2,13%?
Dive Deeper
4AB:ETR
AbbVie Common Stock
€257,60
-2,13%
(-5,60) 1D
19 Nov., 13:18:06 GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 4AB...
Open
€260,10
High
€260,10
Low
€256,00
Mkt. cap
505,56 mjd.
Avg. vol.
576,00
Volume
2,47 k
52-wk high
€272,20
52-wk low
€162,85
No. of employees
57 k
Open
€260,10
High
€260,10
Low
€256,00
Mkt. cap
505,56 mjd.
Avg. vol.
576,00
Volume
2,47 k
52-wk high
€272,20
52-wk low
€162,85
No. of employees
57 k
News stories
From web sources and news partners
Profile
AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues. The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'. Wikipedia
About AbbVie Common Stock
CEORobert A. Michael
Employees57 k
Founded10 Apr. 2012
HeadquartersNorth Chicago, Illinois, Verenigde State van Amerika
SectorHealth Care
Industry-
Websiteabbvie.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Des. 2025
Mrt. 2026
Jun. 2026
Sep. 2026
Revenue
16,62 mjd.
15,00 mjd.
16,99 mjd.
17,40 mjd.
Cost of goods sold
4,55 mjd.
4,22 mjd.
4,29 mjd.
4,28 mjd.
Cost of revenue
4,55 mjd.
4,22 mjd.
4,29 mjd.
4,28 mjd.
Research and development expenses
2,58 mjd.
2,47 mjd.
2,34 mjd.
2,45 mjd.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,82 mjd.
3,49 mjd.
3,55 mjd.
3,80 mjd.
Operating expense
6,40 mjd.
5,96 mjd.
5,90 mjd.
6,23 mjd.
Total operating expenses
10,95 mjd.
10,18 mjd.
10,19 mjd.
10,51 mjd.
Operating income
5,67 mjd.
4,82 mjd.
6,80 mjd.
6,89 mjd.
Other non operating income
120,00 m.
-3,00 m.
-55,00 m.
37,00 m.
EBT including unusual items
2,67 mjd.
1,04 mjd.
4,28 mjd.
4,83 mjd.
EBT excluding unusual items
5,12 mjd.
4,19 mjd.
6,07 mjd.
6,19 mjd.
Income tax expense
853,00 m.
342,00 m.
662,00 m.
609,00 m.
Effective tax rate
31,97%
32,92%
15,47%
12,61%
Other operating expenses
-
-
-
-18,00 m.
Net income
1,82 mjd.
695,00 m.
3,61 mjd.
4,22 mjd.
Net profit margin
10,93%
4,63%
21,27%
24,24%
Earnings per share
2,71
2,65
3,65
3,82
Interest and investment income
59,00 m.
72,00 m.
67,00 m.
102,00 m.
Interest expense
-714,00 m.
-717,00 m.
-746,00 m.
-802,00 m.
Net interest expenses
-655,00 m.
-645,00 m.
-679,00 m.
-700,00 m.
Depreciation and amortization charges
-
-
-
-
EBITDA
7,66 mjd.
6,76 mjd.
8,68 mjd.
8,75 mjd.
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google-programme